Beigene Ltd (NASDAQ:BGNE)
| 224.72 Delayed Data As of Mar 27 |  +5.07 / +2.31%Today’s Change | 118.18 Today|||52-Week Range 280.62 | +2.17% Year-to-Date |
Latest BGNE News | Press Releases
| Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate Mar 16 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 219.71 |
| Today’s open | 219.33 |
| Day’s range | 219.00 - 224.79 |
| Volume | 181,107 |
| Average volume (3 months) | 253,003 |
| Market cap | $21.0B |
Data as of 3:59pm ET, 03/27/2023
Growth & Valuation
| Earnings growth (last year) | -27.55% |
| Earnings growth (this year) | +31.68% |
| Earnings growth (next 5 years) | -18.89% |
| Revenue growth (last year) | +20.37% |
| P/E ratio | NM |
| Price/Sales | 16.02 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TEVATeva Pharmaceutical | +0.29 | +3.44% |
| BBIOBridgeBio Pharma Inc | -0.58 | -3.89% |
| IDRSFIdorsia Ltd | +0.25 | +2.25% |
| OASMYVivesto AB | 0.00 | 0.00% |
Data as of 4:00pm ET, 03/27/2023
Financials
| Next reporting date | May 4, 2023 |
| EPS forecast (this quarter) | -$3.50 |
| Annual revenue (last year) | $1.4B |
| Annual profit (last year) | -$2.0B |
| Net profit margin | -141.52% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters George Town, George Town |
Forecasts
